Physician profile
Anil Gupta
NPI 1912961558
$2,190.36
in general payments reported to CMS, 2019-2025
25 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.20 · 2020: $59.72 · 2021: $463 · 2022: $592 · 2023: $695 · 2024: $60.46 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $305.61 | 2021-2023 | Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $273.58 | 2025 | Symbravo |
| Abbvie INC. | $180.80 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.48 | 2022-2024 | Caplyta |
| Novo Nordisk INC | $157.76 | 2021-2023 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $142.85 | 2023 | Epclusa |
| Alkermes, INC. | $134.85 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.89 | 2021 | |
| Abbott Laboratories | $102.72 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Lilly USA, LLC | $90.26 | 2021 | |
| Novartis Pharmaceuticals Corporation | $85.35 | 2019-2023 | |
| Indivior INC. | $84.51 | 2021-2023 | Sublocade, Perseris |
| Ucb, INC. | $46.12 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $38.09 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $34.65 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $33.80 | 2019 | |
| Eisai INC. | $33.64 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $33.27 | 2020 | |
| Amgen INC. | $20.41 | 2022 | |
| G Medical Diagnostic Services, INC. | $19.82 | 2022 | |
| Lundbeck LLC | $17.33 | 2022 | |
| Neurocrine Biosciences, INC. | $16.50 | 2021 | |
| Mylan Specialty L.P. | $15.13 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.24 | 2024 | Quviviq |
| Amarin Pharma, INC. | $11.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anil Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.